CAPR צמיחת הכנסות רבעונית Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. (CAPR) - לוגו תאגידי

Anticipation of the registration application for the primary Duchenne muscular dystrophy drug is creating positive momentum, and GURU.Markets data informs this chart, where the QoQ revenue growth rate reaches 0.00. The business foundation of Capricor Therapeutics (CAPR) relies on a team of geneticists developing cell therapy and cost optimization through the outsourcing of production to third-party contractors.

Capricor (CAPR) - קצב צמיחת הכנסות לרבעון מ-04.07.2022 עד 20.11.2026

פילוחי נתונים אנליטיים מרוכזים עבור Capricor Therapeutics (CAPR)

- ציטוטים נוכחיים ותחזית שווי ממוצעת:
ניתוח מסכם של החברה:CAPR - Capricor
מוצרים מיוצרים של Capricor

The resilience of Capricor Therapeutics (CAPR) is based on the synergy between highly qualified scientists and innovations in the field of cardiac cell therapy. By analyzing the quarterly growth of total revenue, an investor can see the real efficiency of commercializing these developments. This metric measures the rate of change in sales within the daily trend, excluding one-time anomalies to assess market conditions. The steady growth of this indicator confirms the fundamental value of the assets and justifies the fair value of the business.

חברות מתחרות